|
1
|
Peretz D, Williamson RA, Kaneko K, Vergara
J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR,
Rudd PM, et al: Antibodies inhibit prion propagation and clear cell
cultures of prion infectivity. Nature. 412:739–743. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aguzzi A: Prion diseases of humans and
farm animals: Epidemiology, genetics, and pathogenesis. J
Neurochem. 97:1726–1739. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scheckel C and Aguzzi A: Prions, prionoids
and protein misfolding disorders. Nat Rev Genet. 19:405–418. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aguzzi A and Heikenwalder M: Prion
diseases: Cannibals and garbage piles. Nature. 423:127–129. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forloni G, Chiesa R, Bugiani O, Salmona M
and Tagliavini F: Review: PrP 106-126-25 years after. Neuropathol
Appl Neurobiol. 45:430–440. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fioriti L, Angeretti N, Colombo L, De
Luigi A, Colombo A, Manzoni C, Morbin M, Tagliavini F, Salmona M,
Chiesa R and Forloni G: Neurotoxic and gliotrophic activity of a
synthetic peptide homologous to Gerstmann-Sträussler-Scheinker
disease amyloid protein. J Neurosci. 27:1576–1583. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fioriti L, Quaglio E, Massignan T, Colombo
L, Stewart RS, Salmona M, Harris DA, Forloni G and Chiesa R: The
neurotoxicity of prion protein (PrP) peptide 106–126 is independent
of the expression level of PrP and is not mediated by abnormal PrP
species. Mol Cell Neurosci. 28:165–176. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Villa A, Mark AE, Saracino GA, Cosentino
U, Pitea D, Moro G and Salmona M: Conformational polymorphism of
the PrP106-126 peptide in different environments: A molecular
dynamics study. J Phys Chem B. 110:1423–1428. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Corsaro A, Thellung S, Villa V, Principe
DR, Paludi D, Arena S, Millo E, Schettini D, Damonte G, Aceto A, et
al: Prion protein fragment 106–126 induces a p38 MAP
kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells
independently from the amyloid fibril formation. Ann NY Acad Sci.
1010:610–622. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Troglitazone, . LiverTox: Clinical and
Research Information on Drug-Induced Liver Injury. National
Institute of Diabetes and Digestive and Kidney Diseases; Bethesda,
MD: 2012
|
|
11
|
Frias JP, Yu JG, Kruszynska YT and Olefsky
JM: Metabolic effects of troglitazone therapy in type 2 diabetic,
obese, and lean normal subjects. Diabetes care. 23:64–69. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chandra V, Huang P, Hamuro Y, Raghuram S,
Wang Y, Burris TP and Rastinejad F: Structure of the intact
PPAR-gamma-RXR-nuclear receptor complex on DNA. Nature.
456:350–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lehmann JM, Moore LB, Smith-Oliver TA,
Wilkison WO, Willson TM and Kliewer SA: An antidiabetic
thiazolidinedione is a high affinity ligand for peroxisome
proliferator-activated receptor gamma (PPAR gamma). J Biol Chem.
270:12953–12956. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Olefsky JM and Saltiel AR: PPAR gamma and
the treatment of insulin resistance. Trends Endocrinol Metab.
11:362–368. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong OY, Youn HJ, Jang HY, Jung SH, Noh
EM, Chae HS, Jeong YJ, Kim W, Kim CH and Kim JS: Troglitazone
inhibits matrix metalloproteinase-9 expression and invasion of
breast cancer cell through a peroxisome proliferator-activated
receptor γ-dependent mechanism. J Breast Cancer. 21:28–36. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosen ED and Spiegelman BM: PPARgamma: A
nuclear regulator of metabolism, differentiation, and cell growth.
J Biol Chem. 276:37731–37734. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tontonoz P, Hu E and Spiegelman BM:
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a
lipid-activated transcription factor. Cell. 79:1147–1156. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jain MR, Giri SR, Trivedi C, Bhoi B, Rath
A, Vanage G, Vyas P, Ranvir R and Patel PR: Saroglitazar, a novel
PPARα/γ agonist with predominant PPARα activity, shows
lipid-lowering and insulin-sensitizing effects in preclinical
models. Pharmacol Res Perspect. 3:e001362015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Certo M, Endo Y, Ohta K, Sakurada S,
Bagetta G and Amantea D: Activation of RXR/PPARγ underlies
neuroprotection by bexarotene in ischemic stroke. Pharmacol Res.
102:298–307. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chiang MC, Cheng YC, Nicol CJ, Lin KH, Yen
CH, Chen SJ and Huang RN: Rosiglitazone activation of
PPARγ-dependent signaling is neuroprotective in mutant huntingtin
expressing cells. Exp Cell Res. 338:183–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lecca D, Nevin DK, Mulas G, Casu MA, Diana
A, Rossi D, Sacchetti G, Fayne D and Carta AR: Neuroprotective and
anti-inflammatory properties of a novel non-thiazolidinedione PPARγ
agonist in vitro and in MPTP-treated mice. Neuroscience. 302:23–35.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thouennon E, Cheng Y, Falahatian V, Cawley
NX and Loh YP: Rosiglitazone-activated PPARγ induces neurotrophic
factor-α1 transcription contributing to neuroprotection. J
Neurochem. 134:463–470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang P and Mizushima N: Autophagy and
human diseases. Cell Res. 24:69–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lum JJ, Bauer DE, Kong M, Harris MH, Li C,
Lindsten T and Thompson CB: Growth factor regulation of autophagy
and cell survival in the absence of apoptosis. Cell. 120:237–248.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mizushima N: Autophagy: Process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shintani T and Klionsky DJ: Autophagy in
health and disease: A double-edged sword. Science. 306:990–995.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bjørkøy G, Lamark T, Brech A, Outzen H,
Perander M, Overvatn A, Stenmark H and Johansen T: p62/SQSTM1 forms
protein aggregates degraded by autophagy and has a protective
effect on huntingtin-induced cell death. J Cell Biol. 171:603–614.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakai A, Yamaguchi O, Takeda T, Higuchi Y,
Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, et
al: The role of autophagy in cardiomyocytes in the basal state and
in response to hemodynamic stress. Nat Med. 13:619–624. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Su H, Li F, Ranek MJ, Wei N and Wang X:
COP9 signalosome regulates autophagosome maturation. Circulation.
124:2117–2128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moon JH, Lee JH, Nazim UM, Lee YJ, Seol
JW, Eo SK, Lee JH and Park SY: Human prion protein-induced
autophagy flux governs neuron cell damage in primary neuron cells.
Oncotarget. 7:29989–30002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Beaudoin GM III, Lee SH, Singh D, Yuan Y,
Ng YG, Reichardt LF and Arikkath J: Culturing pyramidal neurons
from the early postnatal mouse hippocampus and cortex. Nat Protoc.
7:1741–1754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cho DH, Lee EJ, Kwon KJ, Shin CY, Song KH,
Park JH, Jo I and Han SH: Troglitazone, a thiazolidinedione,
decreases tau phosphorylation through the inhibition of
cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells
and primary neurons. J Neurochem. 126:685–695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Uryu S, Harada J, Hisamoto M and Oda T:
Troglitazone inhibits both post-glutamate neurotoxicity and
low-potassium-induced apoptosis in cerebellar granule neurons.
Brain Res. 924:229–236. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Redmann M, Benavides GA, Berryhill TF,
Wani WY, Ouyang X, Johnson MS, Ravi S, Barnes S, Darley-Usmar VM
and Zhang J: Inhibition of autophagy with bafilomycin and
chloroquine decreases mitochondrial quality and bioenergetic
function in primary neurons. Redox Biol. 11:73–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shacka JJ, Klocke BJ, Shibata M, Uchiyama
Y, Datta G, Schmidt RE and Roth KA: Bafilomycin A1 inhibits
chloroquine-induced death of cerebellar granule neurons. Mol
Pharmacol. 69:1125–1136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wojtowicz AK, Szychowski KA and Kajta M:
PPAR-γ agonist GW1929 but not antagonist GW9662 reduces
TBBPA-induced neurotoxicity in primary neocortical cells. Neurotox
Res. 25:311–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martin HL, Mounsey RB, Mustafa S, Sathe K
and Teismann P: Pharmacological manipulation of peroxisome
proliferator-activated receptor γ (PPARγ) reveals a role for
anti-oxidant protection in a model of Parkinson's disease. Exp
Neurol. 235:528–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nah J, Pyo JO, Jung S, Yoo SM, Kam TI,
Chang J, Han J, Soo A, An S, Onodera T and Jung YK: BECN1/Beclin 1
is recruited into lipid rafts by prion to activate autophagy in
response to amyloid β 42. Autophagy. 9:2009–2021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Saiki S, Sasazawa Y, Imamichi Y, Kawajiri
S, Fujimaki T, Tanida I, Kobayashi H, Sato F, Sato S, Ishikawa K,
et al: Caffeine induces apoptosis by enhancement of autophagy via
PI3K/Akt/mTOR/p70S6K inhibition. Autophagy. 7:176–187. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kumar D, Shankar S and Srivastava RK:
Rottlerin-induced autophagy leads to the apoptosis in breast cancer
stem cells: molecular mechanisms. Mol Cancer. 12:1712013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arsikin K, Kravic-Stevovic T, Jovanovic M,
Ristic B, Tovilovic G, Zogovic N, Bumbasirevic V, Trajkovic V and
Harhaji-Trajkovic L: Autophagy-dependent and -independent
involvement of AMP-activated protein kinase in 6-hydroxydopamine
toxicity to SH-SY5Y neuroblastoma cells. Biochim Biophys Acta.
1822:1826–1836. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee JH, Yoon YM, Han YS, Jung SK and Lee
SH: Melatonin protects mesenchymal stem cells from
autophagy-mediated death under ischaemic ER-stress conditions by
increasing prion protein expression. Cell Prolif. 52:e125452019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jiang C, Ting AT and Seed B: PPAR-gamma
agonists inhibit production of monocyte inflammatory cytokines.
Nature. 391:82–86. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ricote M, Li AC, Willson TM, Kelly CJ and
Glass CK: The peroxisome proliferator-activated receptor-gamma is a
negative regulator of macrophage activation. Nature. 391:79–82.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Combs CK, Johnson DE, Karlo JC, Cannady SB
and Landreth GE: Inflammatory mechanisms in Alzheimer's disease:
Inhibition of beta-amyloid-stimulated proinflammatory responses and
neurotoxicity by PPARgamma agonists. J Neurosci. 20:558–567. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Beheshti F, Hosseini M, Hashemzehi M,
Soukhtanloo M, Khazaei M and Shafei MN: The effects of PPAR-γ
agonist pioglitazone on hippocampal cytokines, brain-derived
neurotrophic factor, memory impairment, and oxidative stress status
in lipopolysaccharide-treated rats. Iran J Basic Med Sci.
22:940–948. 2019.PubMed/NCBI
|
|
48
|
Zhang H, Gong M and Luo X:
Methoxytetrahydro-2H-pyran-2-yl)methyl benzoate inhibits spinal
cord injury in the rat model via PPAR-γ/PI3K/p-Akt activation.
Environ Toxicol. 35:714–721. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
de Brito TV, Júnior GJD, da Cruz Júnior
JS, Silva RO, da Silva Monteiro CE, Franco AX, Vasconcelos DFP, de
Oliveira JS, da Silva Costa DV, Carneiro TB, et al: Gabapentin
attenuates intestinal inflammation: Role of PPAR-gamma receptor.
Eur J Pharmacol. 873:1729742020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Khasabova IA, Khasabov SG, Olson JK,
Uhelski ML, Kim AH, Albino-Ramírez AM, Wagner CL, Seybold VS and
Simone DA: Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked
neuropathic pain by protecting against oxidative stress. Pain.
160:688–701. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aoun P, Watson DG and Simpkins JW:
Neuroprotective effects of PPARgamma agonists against oxidative
insults in HT-22 cells. Eur J Pharmacol. 472:65–71. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jodeiri Farshbaf M, Forouzanfar M, Ghaedi
K, Kiani-Esfahani A, Peymani M, Shoaraye Nejati A, Izadi T,
Karbalaie K, Noorbakhshnia M, Rahgozar S, et al: Nurr1 and PPARγ
protect PC12 cells against MPP(+) toxicity: Involvement of
selective genes, anti-inflammatory, ROS generation, and
antimitochondrial impairment. Mol Cell Biochem. 420:29–42. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mahmood DFD, Jguirim-Souissi I, Khadija
EH, Blondeau N, Diderot V, Amrani S, Slimane MN, Syrovets T, Simmet
T and Rouis M: Peroxisome proliferator-activated receptor gamma
induces apoptosis and inhibits autophagy of human monocyte-derived
macrophages via induction of cathepsin L: Potential role in
atherosclerosis. J Biol Chem. 286:28858–28866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yao J, Zheng K and Zhang X: Rosiglitazone
exerts neuroprotective effects via the suppression of neuronal
autophagy and apoptosis in the cortex following traumatic brain
injury. Mol Med Rep. 12:6591–6597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gao N, Yao X, Jiang L, Yang L, Qiu T, Wang
Z, Pei P, Yang G, Liu X and Sun X: Taurine improves low-level
inorganic arsenic-induced insulin resistance by activating
PPARγ-mTORC2 signalling and inhibiting hepatic autophagy. J Cell
Physiol. 234:5143–5152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hu C, Chen C, Chen J, Xiao K, Wang J, Shi
Q, Ma Y, Gao LP, Wu YZ, Liu L, et al: The low levels of nerve
growth factor and its upstream regulatory kinases in prion
infection is reversed by resveratrol. Neurosci Res. 162:52–62.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jeong JK, Moon MH, Bae BC, Lee YJ, Seol
JW, Kang HS, Kim JS, Kang SJ and Park SY: Autophagy induced by
resveratrol prevents human prion protein-mediated neurotoxicity.
Neurosci Res. 73:99–105. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tagliavini F, Forloni G, D'Ursi P, Bugiani
O and Salmona M: Studies on peptide fragments of prion proteins.
Adv Protein Chem. 57:171–201. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ilitchev AI, Giammona MJ, Olivas C, Claud
SL, Lazar Cantrell KL, Wu C, Buratto SK and Bowers MT:
Hetero-oligomeric amyloid assembly and mechanism: Prion fragment
PrP(106–126) catalyzes the islet amyloid polypeptide β-hairpin. J
Am Chem Soc. 140:9685–9695. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Singh N, Gu Y, Bose S, Kalepu S, Mishra RS
and Verghese S: Prion peptide 106–126 as a model for prion
replication and neurotoxicity. Front Biosci. 7:a60–a71. 2002.
View Article : Google Scholar
|
|
61
|
Herrmann US, Sonati T, Falsig J, Reimann
RR, Dametto P, O'Connor T, Li B, Lau A, Hornemann S, Sorce S, et
al: Prion infections and anti-PrP antibodies trigger converging
neurotoxic pathways. PLoS Pathog. 11:e10046622015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tremblay P, Ball HL, Kaneko K, Groth D,
Hegde RS, Cohen FE, DeArmond SJ, Prusiner SB and Safar JG: Mutant
PrPSc conformers induced by a synthetic peptide and several prion
strains. J Virol. 78:2088–2099. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhu C, Herrmann US, Li B, Abakumova I,
Moos R, Schwarz P, Rushing EJ, Colonna M and Aguzzi A: Triggering
receptor expressed on myeloid cells-2 is involved in prion-induced
microglial activation but does not contribute to prion pathogenesis
in mouse brains. Neurobiol Aging. 36:1994–2003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Giaccone G and Moda F: PMCA applications
for prion detection in peripheral tissues of patients with variant
creutzfeldt-jakob disease. Biomolecules. 10:4052020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Haley NJ and Hoover EA: Chronic wasting
disease of cervids: Current knowledge and future perspectives. Annu
Rev Anim Biosci. 3:305–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kaufman SK and Diamond MI: Prion-like
propagation of protein aggregation and related therapeutic
strategies. Neurotherapeutics. 10:371–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Aguzzi A and Calella AM: Prions: Protein
aggregation and infectious diseases. Physiol Rev. 89:1105–1152.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhu C, Li B, Frontzek K, Liu Y and Aguzzi
A: SARM1 deficiency up-regulates XAF1, promotes neuronal apoptosis,
and accelerates prion disease. J Exp Med. 216:743–756. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Jeong JK and Park SY: Melatonin regulates
the autophagic flux via activation of alpha-7 nicotinic
acetylcholine receptors. J Pineal Res. 59:24–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Damme M, Suntio T, Saftig P and Eskelinen
EL: Autophagy in neuronal cells: General principles and
physiological and pathological functions. Acta Neuropathol.
129:337–362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lee JH, Jeong JK and Park SY:
Sulforaphane-induced autophagy flux prevents prion protein-mediated
neurotoxicity through AMPK pathway. Neuroscience. 278:31–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ciechanover A and Kwon YT: Degradation of
misfolded proteins in neurodegenerative diseases: Therapeutic
targets and strategies. Exp Mol Med. 47:e1472015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Nakagaki T, Satoh K, Ishibashi D, Fuse T,
Sano K, Kamatari YO, Kuwata K, Shigematsu K, Iwamaru Y, Takenouchi
T, et al: FK506 reduces abnormal prion protein through the
activation of autolysosomal degradation and prolongs survival in
prion-infected mice. Autophagy. 9:1386–1394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kovalevich J and Langford D:
Considerations for the use of SH-SY5Y neuroblastoma cells in
neurobiology. Methods Mol Biol. 1078:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Forster JI, Köglsberger S, Trefois C, Boyd
O, Baumuratov AS, Buck L, Balling R and Antony PM: Characterization
of differentiated SH-SY5Y as neuronal screening model reveals
increased oxidative vulnerability. J Biomol Screen. 21:496–509.
2016. View Article : Google Scholar : PubMed/NCBI
|
